In conclusion, fucosylation of HLA-DRB1 is a key regulator of itIC abundance in melanomas, and this mechanism, together with fucosylation-regulated CD4+ T cell biology, can be therapeutically exploited using oral l-fuc administration. This evidence concerns the gene HLA-DRB1 and melanoma.